zovegalisib + fulvestrant

**Zovegalisib + fulvestrant** is an investigational combination regimen consisting of zovegalisib (RLY-2608), an oral, mutant-selective, allosteric inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα), and fulvestrant, an intramuscular selective estrogen receptor degrader (SERD). Developed by Relay Therapeutics, this combination is designed to treat patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer harboring PIK3CA mutations. By combining mutant-selective PI3Kα inhibition with estrogen receptor degradation, the regimen aims to overcome endocrine therapy resistance while minimizing the off-target toxicities (such as hyperglycemia and diarrhea) typically associated with non-selective, orthosteric PI3K inhibitors. The combination has received FDA Breakthrough Therapy designation and is being evaluated in the Phase 3 ReDiscover-2 trial.

Other names

Faslodex + RLY-2608Faslodex + zovegalisibRLY-2608 + fulvestrantRLY-2608 and fulvestrantRLY2608 and fulvestrantRLY 2608 and fulvestrantRLY-2608 plus fulvestrantRLY2608 plus fulvestrantRLY 2608 plus fulvestrantRLY-2608/fulvestrantfulvestrant + RLY-2608fulvestrant + zovegalisibfulvestrant and RLY-2608fulvestrant and zovegalisibfulvestrant plus RLY-2608fulvestrant plus zovegalisibfulvestrant/zovegalisibzovegalisib + fulvestrantzovegalisib and fulvestrantzovegalisib plus fulvestrantzovegalisib/fulvestrant